MNKD Mannkind

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.

Company profile

Michael Castagna
Fiscal year end
IRS number

MNKD stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


25 Feb 21
13 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Mannkind earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 67.16M 67.16M 67.16M 67.16M 67.16M 67.16M
Cash burn (monthly) (positive/no burn) (positive/no burn) 8.8M 4.79M (positive/no burn) 2.34M
Cash used (since last report) n/a n/a 30.42M 16.54M n/a 8.1M
Cash remaining n/a n/a 36.75M 50.62M n/a 59.06M
Runway (months of cash) n/a n/a 4.2 10.6 n/a 25.2

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 Mar 21 Michael Castagna Common Stock,$.01 par value Buy Aquire P Yes No 3.38 3,000 10.14K 3,000
31 Jan 21 Stuart A Tross Common Stock, $0.01 Par Value Buy Aquire P No No 1.33 5,000 6.65K 481,991
31 Jan 21 Michael Castagna Common Stock, $0.01 Par Value Buy Aquire P No No 1.33 5,000 6.65K 1,117,560
31 Jan 21 Steven B. Binder Common Stock, $0.01 Par Value Buy Aquire P No No 1.33 1,557 2.07K 398,822
28 Dec 20 Stuart A Tross Common Stock, $.01 Par Value Payment of exercise Dispose F No No 3.33 1,729 5.76K 476,991

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

30.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 146 136 +7.4%
Opened positions 29 16 +81.3%
Closed positions 19 21 -9.5%
Increased positions 52 35 +48.6%
Reduced positions 36 36
13F shares
Current Prev Q Change
Total value 446.41M 227.75M +96.0%
Total shares 75.1M 68.86M +9.1%
Total puts 1.37M 795.8K +71.7%
Total calls 969.8K 628.9K +54.2%
Total put/call ratio 1.4 1.3 +11.3%
Largest owners
Shares Value Change
BLK Blackrock 17.98M $56.26M +1.8%
Vanguard 12.29M $38.47M +8.5%
STT State Street 8.85M $27.69M +137.4%
FMR 3.73M $11.68M -18.1%
Avoro Capital Advisors 3.5M $10.96M NEW
Geode Capital Management 3.29M $10.29M +7.7%
NTRS Northern Trust 2.53M $7.91M -0.7%
Millennium Management 2.07M $6.48M NEW
Charles Schwab Investment Management 1.5M $4.69M +2.0%
Two Sigma Advisers 1.46M $4.56M +72.3%
Largest transactions
Shares Bought/sold Change
STT State Street 8.85M +5.12M +137.4%
Avoro Capital Advisors 3.5M +3.5M NEW
Emerald Advisers 0 -3.16M EXIT
Emerald Mutual Fund Advisers Trust 0 -2.92M EXIT
Millennium Management 2.07M +2.07M NEW
MS Morgan Stanley 1.19M -2.03M -63.0%
Vanguard 12.29M +961.64K +8.5%
FMR 3.73M -822.78K -18.1%
EAM Global Investors 702.98K +702.98K NEW
Two Sigma Advisers 1.46M +611.3K +72.3%

Financial report summary

Content analysis
H.S. junior Avg
New words: Absent, accuracy, AfrezzaAssist, Alejandro, anesthesiologist, appliance, batch, belief, beneficiary, Biden, Britain, buyer, call, calling, cannabidiol, cap, CECL, Chancery, Chase, choice, chosen, churn, clarity, clofazimine, communicable, complaint, congenital, constitutionality, contemplated, contrary, controversy, County, covertly, culture, denial, di, dictated, disbursement, discourage, discretionary, diverge, doctrine, DPI, duration, duty, economy, Electric, electrical, eleven, EMA, endocrine, energy, entertain, epidemic, evidenced, expedited, facially, faith, fiduciary, forfeited, forgiven, forum, fullest, Galindo, GE, Great, home, hospital, hypothalamic, hypothyroidism, imatinib, impede, inapplicable, inconsistent, Indiana, indispensable, Inline, instance, interpolated, interstitial, intervention, joinder, JPMorgan, Kingdom, lab, leverage, levothyroxine, LOI, Los, Lyumjev, magnitude, margin, mathematical, Medtronic, Mexico, MHRA, midst, Monterrey, movement, mycobacterial, NaN, nationwide, nebulized, nonemployee, Northern, NTM, nurse, oppose, orphan, overtly, pandemic, Paycheck, percentile, pituitary, PNQ, PPP, preliminary, prioritization, prioritize, prorated, pulmonology, QrumPharma, quarantined, qui, reacquired, reassessment, recession, recurrent, reexamining, refund, regime, regrettable, reopened, residence, resignation, resumed, reward, risky, RSU, SBA, secondary, sentiment, sequester, shelter, situation, sodium, solid, speculative, spread, stretch, strike, tam, tangible, tariff, telecommunication, terrorism, tertiary, threat, Thyquidity, thyroidal, tie, timeframe, TSR, Tyvaso, unbilled, underwent, unemployment, unforgiven, unimproved, unnecessary, unrecoverable, usability, vaccination, venue, Vertice, vi, vii, virtual, visit, war, week, whistleblower, wholly, withheld, workweek, worth, XBRL
Removed: absorption, advisory, advocacy, Alinaya, allegation, Amylin, approving, attest, augment, beneficially, biology, body, borrow, broader, capability, Center, chemistry, claiming, Clinic, Concurrently, confirm, consistently, consultant, contracting, convene, Dame, deposited, detailing, dispersed, embedded, excretion, explanatory, expressed, feature, finalize, Fujisawa, geographically, glucose, Graduate, graduating, guided, healthy, injected, inspect, institution, institutional, integrated, internally, introduced, invested, investigator, IRB, Kellogg, Kendall, malfunctioned, McCauley, mealtime, metabolism, Minnesota, municipal, NED, Nicollet, Northridge, Northwestern, Notre, Olaf, optimal, outweigh, overlap, paragraph, Park, participating, Patrick, payor, pertain, pharmacology, placement, population, potency, producing, protocol, purity, rank, rated, recalling, recur, refusing, release, repeated, Rosabel, round, seizing, separated, sequential, shown, South, St, supplement, suspending, tolerability, tolerance, traditionally, unacceptable, unaudited, underperform, undertaken, unqualified, unwarranted, withdrawing, Yamanouchi